About Hutchison China MediTech
Hutchison China MediTech is a publicly listed company based in Hong Kong (China) founded in 2005. Immunotherapies for cancer and immunological diseases are developed. The company has 1,810 employees. Its website hutch-med.com draws about 13 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Founded in 2005 and headquartered in Hong Kong, China, the company operates in the biotechnology sector. Focus is placed on developing immunotherapies targeting cancer and immunological diseases. A portfolio of drugs, including Savolitinib, Surufatinib, Fruquintinib, HMPL-523, HMPL-689, HMPL-453, HMPL-306, HMPL-295, and Eptinib, is maintained. These are utilized as potent oral inhibitors of vascular endothelial growth factor receptors, either alone or combined with other treatments.
- Headquarters Hong Kong, China
- Employees 1,810
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website hutch-med.com
- Social LinkedIn X
- Legal Name Hutchmed (China) Limited
- Annual Revenue$549.83 M (USD)-13.04as on Dec 31, 2025
- Net Profit$457.34 M (USD)1109.95as on Dec 31, 2025
- EBITDA-$32.35 M (USD)1.06as on Dec 31, 2025
- Latest Funding Round$15M (USD), Post-IPO
Mar 2022
- InvestorsAstrazeneca
& 2 more
- Employee Count1,810
Funding Insights of Hutchison China MediTech
- Total Rounds 3
- Last Round Post-IPO — $15M
- First Round $100M
(Jun 2020)
- Investors Count 3
All 3 funding rounds of Hutchison China MediTech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $15M | Post-IPO | – | – | |
| Apr 2021 | $100M | Post-IPO | – | – | |
| Jun 2020 | $100M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Hutchison China MediTech
Hutchison China MediTech has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, EQT and General Atlantic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Hutchison China MediTech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hutchison China MediTech
70 people are tracked at Hutchison China MediTech (41 in leadership, 8 in board & advisors, 21 in team); the tracked headcount is 1,810.
| Name | Role | Group |
|---|---|---|
Caron Li | Vice President | Leadership |
Weiguo Su | CEO, Executive Director & Chief Scientific Officer | Leadership |
Johnny Cheng | CFO & Executive Director | Leadership |
Junjie Zhou | President, Shanghai Hutchison Pharmaceuticals | Leadership |
Tammie C. | Director, Head Of Data Management | Leadership |
Michael Shi | EVP, Head of R&D & Chief Medical Officer, China | Leadership |
Hong Chen | COO & SVP, China | Leadership |
Martin Beneš | Director Clinical Operations | Leadership |
Nick Lawn | Director European Clinical Operations | Leadership |
Catherine Chao | Director, Macau Operations | Leadership |
Ann Xu | Vp, Hematologic Malignancy BU | Leadership |
An Li | Head/director Of Statistical Programming | Leadership |
Mark Lee | Senior Vice President Corporate Finance Development | Leadership |
Laura Chio | Associate Director Of Finance | Leadership |
Christopher Kwok | Associate Director, Financial Reporting | Leadership |
Hank Lam | Director, Finance | Leadership |
Kate Yi | Senior Director Finance & IT | Leadership |
Lorenso Chiu | Senior Vice President Finance- Business Development & Reporting | Leadership |
Xiaoshuai Wei | Associate Director Clinical Project Management | Leadership |
Joyce Chau | Vice President Financial Reporting | Leadership |
50 more people are available in the full profile.
Complete people profiles for Hutchison China MediTech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Hutchison China MediTech
Hutchison China MediTech is a publicly listed company on the HKEX with ticker symbol 13 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jun 2021
- Listed onHKG: 13
- Listed entityHUTCHMED (China) Limited
- Exchange sectorHealth technology
- ISINKYG4672N1198
- Share price21.42 HKD (+1.23% on the day) · 2026-10-14
- Market capitalisation18,458,611,515.00 HKD
- Price to earnings135.0
- EPS (diluted, trailing year)0.16 HKD
- Volume (last session)4,033,500
Financials of Hutchison China MediTech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.28B HKD | 3.56B HKD | -251.8M HKD |
| 2024 | 4.92B HKD | 294.4M HKD | -254.5M HKD |
| 2023 | 6.56B HKD | 789.0M HKD | 199.9M HKD |
| 2022 | 3.34B HKD | -2.83B HKD | -3.16B HKD |
| 2021 | 2.77B HKD | -1.51B HKD | -2.62B HKD |
Detailed financial statements for Hutchison China MediTech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Hutchison China MediTech
4 dated milestones of Hutchison China MediTech across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Hutchison China MediTech is founded.
- Funding First funding round of $100.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $15.0M.
Web traffic of Hutchison China MediTech
The website of Hutchison China MediTech (hutch-med.com) receives about 13.2K visits a month and ranks #1,517,293 among all websites worldwide, #2,005 in Biotechnology and Pharmaceuticals.
- Monthly visits13.2K
▼ 28.7% vs previous month
- Unique visitors8.1K
per month
- Global rank#1,517,293
among all websites
- Category rank#2,005
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit1.5
- Average visit21 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with Hutchison China MediTech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astrazeneca.com.cn | 100% | #6,860,486 | View details | ||
cjpi.org.cn | cjpi.org.cn | 84% | #3,726,577 | – | |
| pharnexcloud.com | 84% | 51.6K | #713,781 | View details | |
| carestream.com | 62% | 51.7K | #557,978 | View details | |
| liangyihui.net | 55% | 28.3K | #1,136,814 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Hutchison China MediTech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hutchison China Meditech
Complete news archive for Hutchison China MediTech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hutchison China MediTech
Hutchison China MediTech was founded in 2005 and raised its 1st funding round 15 years after it was founded.
Hutchison China MediTech is headquartered in Hong Kong, China.
Hutchison China MediTech has 1,810 employees.
Annual revenue of Hutchison China MediTech is $549.83M as on Dec 31, 2025.
Founded in 2005 and headquartered in Hong Kong, China, the company operates in the biotechnology sector. Focus is placed on developing immunotherapies targeting cancer and immunological diseases. A portfolio of drugs, including Savolitinib, Surufatinib, Fruquintinib, HMPL-523, HMPL-689, HMPL-453, HMPL-306, HMPL-295, and Eptinib, is maintained. These are utilized as potent oral inhibitors of vascular endothelial growth factor receptors, either alone or combined with other treatments.
Yes, Hutchison China MediTech is publicly traded on HKEX under the ticker symbol 13.
Hutchison China MediTech has 3 investors. Key investors include Astrazeneca, EQT, and General Atlantic.